Literature DB >> 29863943

Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature.

Musa Alzahrani1, Ibrahim Alrumaih2, Fahad Alhamad3, Ahmed Abdel Warith1.   

Abstract

Pipercillin-tazobactam is a frequently used antibiotic that has a broad spectrum of antibacterial activity. The development of severe thrombocytopenia following the use of piperacillin-tazobactam is unusual. Several mechanisms have been proposed for the pathogenesis of thrombocytopenia in this setting which include immune and non-immune causes. Multiple case reports have shown the ability of piperacillin-tazobactam to cause drug-induced immune thrombocytopenia, likely through formation of antibodies that recognize platelets in the presence of soluble piperacillin. However, severe and rapid development of thrombocytopenia that occurs in association with reexposure to piperacillin-tazobactam has not been clearly demonstrated in the literature. We present two cases in whom severe and rapid development of thrombocytopenia has occurred subsequent to administration of piperacillin-tazobactam with a prior history of recent exposure to the drug. In both cases, thrombocytopenia improved immediately and dramatically following withdrawal of piperacillin-tazobactam with initiation of steroids and intravenous immunoglubulins, suggesting and immune related drug-induced thrombocytopenia.

Entities:  

Keywords:  Antibiotics; drug-induced thrombocytopenia; piperacillin-tazobactam

Mesh:

Substances:

Year:  2018        PMID: 29863943     DOI: 10.1080/09537104.2018.1468025

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  2 in total

1.  Piperacillin/tazobactam-induced coagulopathy in a patient through a vitamin K-dependent mechanism.

Authors:  Zhenwei Yu; Huadong Chen
Journal:  Eur J Hosp Pharm       Date:  2020-06-17

2.  An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage.

Authors:  Jiawen Lv; Guannan Wu; Fang Zhang; Xin Su
Journal:  Eur J Hosp Pharm       Date:  2021-02-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.